Table 2.
Ongoing clinical trials utilizing immune checkpoint blockade in NKTCL (by 10-Aug-2020).
| Phase | Trial Intervention | Status; Estimated completion date | NCT ID |
|---|---|---|---|
| 1 | MEDI-570 (anti-ICOS antibody) | Recruiting; December 2020 | 02520791 |
| 1 | Pembrolizumab + modified SMILE and ASCT | Recruiting; December 2023 | 03719105 |
| 1/2 | Pembrolizumab Pembrolizumab + copanlisib |
Recruiting; December 2022 | 02535247 |
| 1/2 | Sintilimab + chidamide | Recruiting; February 2025 | 03820596 |
| 1/2 | Pembrolizumab + romidepsin | Active, not recruiting; November 2020 | 03278782 |
| 1/2 | Pembrolizumab + pralatrexate | Recruiting; April 2021 | 03598998 |
| 2 | Nivolumab + talimogene laherparepvec | Recruiting; June 2021 | 02978625 |
| 2 | Pembrolizumab + radiotherapy | Recruiting; November 2020 | 03210662 |
| NA | Cemrelizumab + pegaspargase + apatinib | Recruiting; December 2023 | 04366128 |
ICOS, Inducible T-cell co-stimulator; SMILE, Dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide; ASCT, Allogeneic stem cell transplantation; NA, not availabe.